Ticagrelor For High-Risk Coronary Artery Disease Patients and other Medical Updates – June

Critical Review On Liraglutide For Weight Management Liraglutide is a glucagon like peptide‐1 (GLP‐1) receptor agonist, is a 1.8 mg daily subcutaneous injection was initially approved by the FDA in 2010 as an adjunct therapy to diet and exercise for management of type 2 diabetes. Results from clinical trials repeatedly demonstrated the ability of GLP‐1 analogs … Continue reading Ticagrelor For High-Risk Coronary Artery Disease Patients and other Medical Updates – June